The regulatory agency has granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act target action date of March 19, the biotechnology company said.
Price: 187.09, Change: +2.15, Percent Change: +1.16
|2021 Earnings Projection for Mosaic Lowered|
|Merit Medical Systems' Q1, 2020, and 2021 Earnings L...|
|Earnings Forecast for MGP Ingredients in 2020 Decreased|
|2020 and Q1 Estimates for MercadoLibre Scaled Up but...|
|Q1 and 2020 Estimates for MoneyGram International Sc...|